Near-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing

dc.contributor.authorDurdagi, Serdar
dc.contributor.authorDag, Cagdas
dc.contributor.authorDogan, Berna
dc.contributor.authorYigin, Merve
dc.contributor.authorAvsar, Timucin
dc.contributor.authorBuyukdag, Cengizhan
dc.contributor.authorErol, Ismail
dc.date.accessioned2025-10-29T11:22:45Z
dc.date.issued2021
dc.departmentFakülteler, Temel Bilimler Fakültesi, Kimya Bölümü
dc.description.abstractThe COVID-19 pandemic has resulted in 198 million reported infections and more than 4 million deaths as of July 2021 (covid19.who.int). Research to identify effective therapies for COVID-19 includes: (1) designing a vaccine as future protection; (2) de novo drug discovery; and (3) identifying existing drugs to repurpose them as effective and immediate treatments. To assist in drug repurposing and design, we determine two apo structures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease at ambient temperature by serial femtosecond X-ray crystallography. We employ detailed molecular simulations of selected known main protease inhibitors with the structures and compare binding modes and energies. The combined structural and molecular modeling studies not only reveal the dynamics of small molecules targeting the main protease but also provide invaluable opportunities for drug repurposing and structure based drug design strategies against SARS-CoV-2.
dc.description.sponsorshipNational Science Foundation (NSF) Science and Technology Centers grant [NSF-1231306]
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [118C270]
dc.description.sponsorshipU.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-76SF00515]
dc.description.sponsorshipMax-Planck Institute for Medical Research
dc.description.sponsorshipDOE Office of Science through the National Virtual Biotechnology Laboratory, a consortium of DOE national laboratories focused on response to COVID-19
dc.description.sponsorshipBahcesehir University (BAU) Scientific Research Projects (BAP) grant [BAU2020-0101]
dc.description.sponsorshipCoronavirus CARES Act
dc.description.sponsorshipAuthors would like to dedicate this manuscript to the memory of John C. H. Spence. H.D. acknowledges support from National Science Foundation (NSF) Science and Technology Centers grant NSF-1231306 (Biology with X-ray Lasers, BioXFEL) and The Scientific and Technological Research Council of Turkey (TUBITAK) grant (118C270) . H.D. would like to thank Michelle Young, Ritu Khurana, Lori Anne Love, and Tracy Chou for their invaluable support and discussions. The authors would like to thank James Fraser and Galen Correy for their critical reading of our manuscript and their comments. Use of the Linac Coherent Light Source (LCLS) , SLAC National Accelerator Laboratory, is sup-ported by the U.S. Department of Energy, Office of Science, Office of Basic En-ergy Sciences under contract no. DE-AC02-76SF00515. The HERA system for in helium experiments at MFX was developed by Bruce Doak and funded by the Max-Planck Institute for Medical Research. Research was supported by the DOE Office of Science through the National Virtual Biotechnology Labora-tory, a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. The numer-ical calculations reported in this paper were partially performed at TUBITAK ULAKBIM, High Performance and Grid Computing Center (TRUBA resources) . S.D. and I.E. acknowledge TRUBA for the computational resources. S.D. ac-knowledges support from Bahcesehir University (BAU) Scientific Research Projects (BAP) grant (BAU2020-0101) .
dc.identifier.doi10.1016/j.str.2021.07.007
dc.identifier.endpage+
dc.identifier.issn0969-2126
dc.identifier.issn1878-4186
dc.identifier.issue12
dc.identifier.orcid0000-0002-9056-9000
dc.identifier.orcid0000-0001-8841-4811
dc.identifier.orcid0000-0002-3857-7652
dc.identifier.orcid0000-0002-5650-5177
dc.identifier.orcid0000-0002-5292-0808
dc.identifier.orcid0000-0003-1595-431X
dc.identifier.orcid0000-0003-2424-9583
dc.identifier.pmid34403647
dc.identifier.scopus2-s2.0-85112800022
dc.identifier.scopusqualityQ1
dc.identifier.startpage1382
dc.identifier.urihttps://doi.org/10.1016/j.str.2021.07.007
dc.identifier.urihttps://hdl.handle.net/20.500.14854/9109
dc.identifier.volume29
dc.identifier.wosWOS:000728503500005
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCell Press
dc.relation.ispartofStructure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20251020
dc.subjectRespiratory Syndrome-Coronavirus
dc.subjectFemtosecond Crystallography
dc.subjectMolecular-Dynamics
dc.subjectAccurate Docking
dc.subjectGlide
dc.subjectModel
dc.subjectMechanisms
dc.subjectInhibitors
dc.subjectSoftware
dc.subjectCovid-19
dc.titleNear-physiological-temperature serial crystallography reveals conformations of SARS-CoV-2 main protease active site for improved drug repurposing
dc.typeArticle

Dosyalar